Cellceutix Corp Stock Price - CTIX

Best deals to access real time data!
SMALL CAP BASIC
Monthly Subscription
for only
$29.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$59.99
SMALL CAP PRO
Monthly Subscription
for only
$43.59
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN Company Description
Cellceutix Corp. (QB) CTIX Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded DELAYED
  +0.00 +0.00% 0.7199 - - - 0.7199 07:27:18
Bid Price Ask Price Spread Spread % News
0.20 5.00 4.80 96.00% - -
Last Trade Time Type Quantity Stock Price Currency
- - - USD

Cellceutix Corp. (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 94.54M 131.32M $ -12.85M - -7.36 87.14M
Short Interest Short % of Out Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
849.62k 0.65% $ - 0.00% - -

more financials information »

Cellceutix Corp. (QB) News

Date Time Source News Article
4/17/201707:03InvestorsHub NewsWireBahamas Development Corp. (OTC Pink: BDCI) $2.4 Million in..
3/31/201716:25Edgar (US Regulatory)Current Report Filing (8-k)
3/29/201716:13Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
3/27/201711:29Edgar (US Regulatory)Current Report Filing (8-k)
2/16/201707:01Edgar (US Regulatory)Current Report Filing (8-k)
2/09/201716:04Edgar (US Regulatory)Quarterly Report (10-q)
2/09/201709:39Edgar (US Regulatory)Current Report Filing (8-k)

Historical CTIX Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.860.88990.6550.0000182k2M545k-0.1401-16.29%
1 Month1.001.030.6550.0000125k2M331k-0.2801-28.01%
3 Months1.051.160.6550.000069k2M268k-0.3301-31.44%
6 Months1.1251.5050.6550.000029k2M248k-0.4051-36.01%
1 Year1.801.870.6550.000029k2M200k-1.0801-60.01%
3 Years1.814.930.6550.000004M289k-1.0901-60.23%
5 Years0.504.930.00010.000004M270k0.219943.98%

Cellceutix Corp. (QB) Description

An early stage developmental biopharmaceutical company...with six pharmaceutical compound candidates that are designed for treatment of diseases which may be either existing or diseases identified in the future. The Company will initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin, for the treatment of head and neck cancers.
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20170428 12:05:53